[Treatment of congenital hyperuricemia].
D000293:Adolescent; D000493:Allopurinol / Q000627:therapeutic use; D001264:Athetosis; D002648:Child; D006801:Humans; D007042:Hypoxanthines / Q000652:urine; D008607:Intellectual Disability; D007926:Lesch-Nyhan Syndrome / Q000150:complications / Q000188:drug therapy; D008297:Male; D011339:Probenecid / Q000627:therapeutic use; D011686:Purine-Pyrimidine Metabolism, Inborn Errors / Q000150:complications / Q000188:drug therapy*; D011704:Pyelonephritis / Q000209:etiology; D012652:Self Mutilation; D014527:Uric Acid / Q000097:blood* / Q000652:urine; D014545:Urinary Calculi / Q000209:etiology; D014970:Xanthines / Q000652:urine
D007042:Hypoxanthines; D014970:Xanthines; D014527:Uric Acid; D000493:Allopurinol; D011339:Probenecid
Zur Problematik der Behandlung der kongenitalen Hyperurikämie.